Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel Free CRVS Stock Alerts

Corvus Pharmaceuticals (CRVS) Financials

Corvus Pharmaceuticals logo
$15.55 +0.96 (+6.58%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$15.53 -0.02 (-0.13%)
As of 05/8/2026 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Corvus Pharmaceuticals

Annual Income Statements for Corvus Pharmaceuticals

This table shows Corvus Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -31 -36 -56 -47 -47 -6.00 -43 -41 -27 -62 -15
Consolidated Net Income / (Loss)		 -31 -36 -56 -47 -47 -6.00 -43 -41 -27 -62 -15
Net Income / (Loss) Continuing Operations		 -31 -36 -56 -47 -47 -6.00 -43 -41 -27 -62 -15
Total Pre-Tax Income 		-31 -36 -56 -47 -47 -6.00 -43 -31 -22 -59 -13
Total Operating Income		 -14 -37 -57 -49 -49 -44 -39 -33 -23 -28 -43
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 14 37 57 49 49 44 39 33 23 28 43
Selling, General & Admin Expense		 2.42 7.62 10 11 11 12 9.52 8.10 6.88 8.16 9.25
Research & Development Expense		 11 29 46 39 38 32 29 24 17 19 34
Other Special Charges / (Income)		 - - - - - - 0.00 -0.02 0.00 -0.01 0.00
Total Other Income / (Expense), net		 -18 0.60 0.86 2.28 2.18 38 -4.85 1.24 1.58 -32 30
Interest & Investment Income		 0.04 0.60 0.86 0.00 0.00 38 -4.83 1.24 1.58 1.82 2.51
Other Income / (Expense), net		 -18 - - - - -0.23 - 0.00 0.00 -33 27
Other Gains / (Losses), net		 - - - 0.00 - - - -10 -5.28 -3.20 -1.96
Basic Earnings per Share		 ($83.86) ($2.36) ($2.72) ($1.71) ($1.59) ($0.20) ($1.03) - ($0.56) ($1.02) ($0.19)
Weighted Average Basic Shares Outstanding		 373.64K 15.42M 20.49M 27.51M 29.35M 29.48M 41.85M 46.55M 48.03M 60.99M 78.96M
Diluted Earnings per Share		 ($83.86) ($2.36) ($2.72) ($1.71) ($1.59) ($0.20) ($1.03) - ($0.56) ($1.02) ($0.53)
Weighted Average Diluted Shares Outstanding		 373.64K 15.42M 20.49M 27.51M 29.35M 29.48M 41.85M 46.55M 48.03M 60.99M 79.74M
Weighted Average Basic & Diluted Shares Outstanding		 373.64K 15.42M 20.49M 27.51M 29.35M 29.48M 46.57M - 49.04M 68.14M 83.99M

Quarterly Income Statements for Corvus Pharmaceuticals

This table shows Corvus Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.00 -5.72 -5.70 -4.26 -40 -12 15 -8.00 -10 -12 -14
Consolidated Net Income / (Loss)		 -6.00 -6.65 -5.70 -4.26 -40 -12 15 -8.00 -10 -12 -14
Net Income / (Loss) Continuing Operations		 -6.00 -6.65 -5.70 -4.26 -40 -12 15 -8.00 -10 -12 -14
Total Pre-Tax Income 		-5.14 -5.25 -5.94 -3.69 -40 -9.94 16 -7.61 -9.83 -12 -13
Total Operating Income		 -5.56 -5.65 -6.25 -5.94 -7.26 -8.11 -9.92 -10 -11 -12 -15
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 5.56 5.65 6.25 5.94 7.26 8.10 9.92 10 11 12 15
Selling, General & Admin Expense		 1.60 1.65 2.18 1.82 2.03 2.13 2.47 2.39 2.12 2.28 3.70
Research & Development Expense		 3.97 4.00 4.08 4.11 5.22 5.97 7.45 7.87 8.45 9.94 11
Total Other Income / (Expense), net		 -0.44 4.20 0.32 2.25 -32 -0.82 26 2.65 0.74 0.60 1.78
Interest & Investment Income		 -0.87 5.06 0.32 0.43 0.57 2.85 0.53 0.64 0.74 0.60 1.78
Other Income / (Expense), net		 0.00 - 0.00 1.82 -33 -2.35 25 2.01 0.00 - 0.00
Other Gains / (Losses), net		 - - 0.24 -0.58 -0.68 - -0.54 -0.39 -0.32 -0.71 -0.60
Basic Earnings per Share		 ($0.12) ($0.13) ($0.12) ($0.07) ($0.60) ($0.23) $0.21 ($0.10) ($0.12) ($0.18) ($0.15)
Weighted Average Basic Shares Outstanding		 48.97M 48.03M 49.04M 59.71M 66.70M 60.99M 72.13M 77.77M 82.84M 78.96M 90.00M
Diluted Earnings per Share		 ($0.12) ($0.13) ($0.12) ($0.07) ($0.60) ($0.23) ($0.13) ($0.10) ($0.12) ($0.18) ($0.15)
Weighted Average Diluted Shares Outstanding		 48.97M 48.03M 49.04M 59.71M 66.70M 60.99M 75.15M 77.77M 82.84M 79.74M 90.00M
Weighted Average Basic & Diluted Shares Outstanding		 49.04M 49.04M 62.55K 62.55M 64.26M 68.14M 77.11M 74.51M 74.68M 83.99M 84.09M

Annual Cash Flow Statements for Corvus Pharmaceuticals

This table details how cash moves in and out of Corvus Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -8.41 0.95 40 -71 -34 11 47 -50 -0.54 -3.88 -4.16
Net Cash From Operating Activities		 -11 -28 -46 -41 -37 -35 -37 -27 -24 -25 -33
Net Cash From Continuing Operating Activities		 -11 -28 -46 -41 -37 -35 -37 -27 -24 -25 -33
Net Income / (Loss) Continuing Operations		 -31 -36 -56 -47 -47 -6.00 -43 -41 -27 -62 -15
Consolidated Net Income / (Loss)		 -31 -36 -56 -47 -47 -6.00 -43 -41 -27 -62 -15
Depreciation Expense		 0.15 0.59 0.84 0.85 0.74 0.63 0.46 0.37 0.15 0.09 0.11
Amortization Expense		 -0.04 0.65 -0.20 - -0.64 - - -0.17 -0.89 -1.14 -1.35
Non-Cash Adjustments To Reconcile Net Income		 18 3.83 6.23 6.53 7.95 -31 7.76 13 7.43 40 -20
Changes in Operating Assets and Liabilities, net		 1.83 3.45 2.66 -1.42 1.31 1.23 -1.69 1.41 -3.59 -1.65 3.58
Net Cash From Investing Activities		 -92 -43 85 -30 3.26 45 22 -23 16 -27 -7.80
Net Cash From Continuing Investing Activities		 -92 -43 85 -30 3.26 45 22 -23 16 -27 -7.80
Purchase of Property, Plant & Equipment		 -1.75 -2.20 -0.27 -0.36 -0.03 -0.08 -0.01 -0.27 -0.03 0.00 -0.17
Purchase of Investments		 -104 -258 -88 -162 -139 -43 -9.36 -66 -47 -70 -92
Sale of Property, Plant & Equipment		 - - - - - 0.00 0.00 0.02 0.00 0.01 0.00
Sale and/or Maturity of Investments		 14 218 173 132 142 87 31 43 63 43 84
Net Cash From Financing Activities		 95 71 1.44 65 0.02 1.31 62 0.00 7.86 49 36
Net Cash From Continuing Financing Activities		 95 71 1.44 0.39 0.02 1.31 62 0.00 7.86 49 36
Issuance of Debt		 - - - - - - - 0.00 0.00 5.03 0.00
Issuance of Common Equity		 0.00 71 0.71 0.00 0.00 1.22 61 0.00 7.84 25 0.00
Other Financing Activities, net		 0.11 0.00 0.73 0.39 0.02 0.09 1.22 0.00 0.01 19 36

Quarterly Cash Flow Statements for Corvus Pharmaceuticals

This table details how cash moves in and out of Corvus Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 12 -7.49 -5.16 7.39 -10 4.06 -3.74 9.69 -12 1.71 36
Net Cash From Operating Activities		 -5.43 -5.17 -5.16 -5.48 -6.32 -8.47 -8.26 -5.78 -9.57 -9.19 -10
Net Cash From Continuing Operating Activities		 -5.43 -5.17 -5.16 -5.48 -6.32 -8.21 -8.26 -5.78 -9.57 -9.19 -10
Net Income / (Loss) Continuing Operations		 -6.00 -6.65 -5.70 -4.26 -40 -12 15 -8.00 -10 -12 -14
Consolidated Net Income / (Loss)		 -6.00 -6.65 -5.70 -4.26 -40 -12 15 -8.00 -10 -12 -14
Depreciation Expense		 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.03 0.03
Amortization Expense		 -0.25 -0.13 -0.15 -0.22 -0.52 -0.24 -0.29 -0.33 -0.46 -0.26 -0.02
Non-Cash Adjustments To Reconcile Net Income		 1.68 1.18 0.45 -0.47 34 35 -23 -0.37 1.57 2.28 3.25
Changes in Operating Assets and Liabilities, net		 -0.90 0.40 0.22 -0.55 0.14 -31 0.15 2.89 -0.55 1.08 0.06
Net Cash From Investing Activities		 18 -2.32 -0.01 -18 -3.89 -6.08 4.24 -20 -2.62 11 -145
Net Cash From Continuing Investing Activities		 18 -2.32 -0.01 -18 -3.89 -6.08 4.24 -20 -2.62 11 -145
Purchase of Property, Plant & Equipment		 - - 0.00 - - - -0.04 -0.11 - -0.03 -0.09
Purchase of Investments		 -1.82 -11 -4.63 -26 -19 -20 -7.71 -39 -31 -13 -162
Sale and/or Maturity of Investments		 19 9.11 4.62 8.79 15 14 12 19 29 24 17
Net Cash From Financing Activities		 0.34 - 0.00 30 0.05 19 0.28 36 0.36 0.02 191
Net Cash From Continuing Financing Activities		 0.34 - 0.00 30 0.05 19 0.28 36 0.36 0.02 191
Issuance of Common Equity		 0.33 - - - - - 0.00 - - - 189
Other Financing Activities, net		 0.01 - 0.00 - 0.05 19 0.28 36 0.36 0.02 1.34

Annual Balance Sheets for Corvus Pharmaceuticals

This table presents Corvus Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 98 140 95 118 84 86 109 68 46 69 71
Total Current Assets		 96 136 91 116 79 45 71 44 28 54 58
Cash & Equivalents		 4.11 5.05 45 39 5.15 16 63 13 13 8.74 4.58
Short-Term Investments		 90 130 45 75 73 28 5.99 29 15 43 52
Accounts Receivable		 - - - - - - 0.51 0.59 0.03 0.08 0.04
Prepaid Expenses		 1.28 1.14 1.18 0.99 1.36 1.08 1.35 0.77 0.78 2.37 1.43
Plant, Property, & Equipment, net		 1.85 3.25 2.67 2.18 1.46 0.91 0.45 0.35 0.24 0.15 0.22
Total Noncurrent Assets		 0.95 0.87 0.87 0.46 2.84 39 38 24 17 14 13
Long-Term Investments		 - - - - 0.00 37 34 22 16 13 11
Other Noncurrent Operating Assets		 0.95 0.87 0.87 0.46 2.84 2.06 3.43 2.35 1.24 1.81 1.69
Total Liabilities & Shareholders' Equity		 98 140 95 118 84 86 109 68 46 69 71
Total Liabilities		 3.78 7.35 9.94 7.90 13 13 12 12 6.87 36 9.91
Total Current Liabilities		 3.07 5.94 8.97 7.03 10 12 9.69 11 6.87 35 9.38
Accounts Payable		 1.58 1.90 3.45 2.00 2.45 3.47 1.57 1.98 1.53 2.58 2.49
Accrued Expenses		 1.50 4.04 5.52 5.03 6.90 7.60 7.08 7.55 3.97 3.73 6.49
Other Current Liabilities		 - - - - 0.88 1.08 1.05 1.23 1.37 29 0.40
Total Noncurrent Liabilities		 0.71 1.41 0.97 0.87 2.31 1.23 2.60 1.37 0.00 0.94 0.53
Other Noncurrent Operating Liabilities		 0.71 1.41 0.97 0.87 2.31 1.23 2.60 1.37 0.00 0.94 0.53
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Total Equity & Noncontrolling Interests		 -31 133 85 110 71 72 97 56 39 33 61
Total Preferred & Common Equity		 -31 133 85 110 71 72 97 56 39 33 61
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -31 133 85 110 71 72 97 56 39 33 61
Common Stock		 0.44 201 208 281 288 295 362 364 374 431 474
Retained Earnings		 -31 -68 -124 -170 -217 -223 -266 -308 -335 -397 -412
Accumulated Other Comprehensive Income / (Loss)		 -0.05 -0.04 -0.04 -0.03 0.03 0.00 1.87 -0.56 -0.97 -1.29 -0.90

Quarterly Balance Sheets for Corvus Pharmaceuticals

This table presents Corvus Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 58 52 40 65 59 59 89 80 253
Total Current Assets		 38 33 23 48 43 45 76 67 240
Cash & Equivalents		 7.66 20 7.46 15 4.68 5.00 15 2.87 40
Short-Term Investments		 29 12 15 32 37 39 60 63 197
Accounts Receivable		 0.00 0.01 0.03 0.04 0.07 0.08 0.09 0.03 0.04
Prepaid Expenses		 0.89 0.92 0.70 0.98 1.20 1.20 1.29 1.22 3.19
Plant, Property, & Equipment, net		 0.29 0.26 0.21 0.19 0.17 0.17 0.25 0.22 0.28
Total Noncurrent Assets		 20 19 17 16 16 14 13 13 13
Long-Term Investments		 18 17 16 15 15 12 12 12 10
Other Noncurrent Operating Assets		 1.82 1.51 0.95 0.71 0.54 1.72 1.64 1.78 2.47
Total Liabilities & Shareholders' Equity		 58 52 40 65 59 59 89 80 253
Total Liabilities		 8.56 7.65 6.72 13 46 10 9.23 8.71 13
Total Current Liabilities		 7.86 7.30 6.72 13 46 9.28 8.51 8.07 12
Accounts Payable		 2.10 1.40 1.61 1.21 1.87 1.31 3.14 1.97 4.70
Accrued Expenses		 4.46 4.56 4.07 4.30 4.22 3.87 5.01 5.72 6.99
Other Current Liabilities		 1.30 1.34 1.04 7.82 40 4.10 0.36 0.38 0.43
Total Noncurrent Liabilities		 0.70 0.35 0.00 0.00 0.00 0.83 0.73 0.63 0.41
Other Noncurrent Operating Liabilities		 0.70 0.35 - - - 0.83 0.73 0.63 0.41
Commitments & Contingencies		 0.00 0.00 - - - - - - 0.00
Total Equity & Noncontrolling Interests		 49 44 33 51 12 49 80 72 241
Total Preferred & Common Equity		 49 44 33 51 12 49 80 72 241
Preferred Stock		 0.00 0.00 0.00 - - - - - 0.00
Total Common Equity		 49 44 33 51 12 49 80 72 241
Common Stock		 373 374 375 397 398 432 471 473 668
Retained Earnings		 -322 -328 -340 -345 -385 -382 -390 -400 -426
Accumulated Other Comprehensive Income / (Loss)		 -1.37 -1.44 -1.28 -1.36 -0.74 -1.25 -1.15 -1.06 -1.13

Annual Metrics And Ratios for Corvus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Corvus Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 20,911,933.00 21,041,250.00 29,282,086.00 29,405,400.00 28,061,900.00 46,548,458.00 46,553,511.00 49,038,582.00 - 74,681,872.00
DEI Adjusted Shares Outstanding		 0.00 20,911,933.00 21,041,250.00 29,282,086.00 29,405,400.00 28,061,900.00 46,548,458.00 46,553,511.00 49,038,582.00 - 74,681,872.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.74 -2.65 -1.60 -1.59 -0.21 -0.93 -0.89 -0.55 - -0.20
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -9.64 -26 -40 -34 -34 -31 -27 -23 -16 -19 -30
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -40.62% -42.36% -59.21% -49.15%
Earnings before Interest and Taxes (EBIT)		 -31 -37 -57 -49 -49 -44 -39 -33 -23 -61 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -31 -36 -56 -48 -49 -43 -38 -32 -24 -62 -17
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -23 -36 -35 -32 -28 -28 -23 -20 8.06 -55
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.29 -2.10 -5.22 -4.26 -6.87 -9.34 -8.07 -8.07 -4.59 -32 -6.54
Increase / (Decrease) in Invested Capital		 0.00 -2.39 -3.13 0.96 -2.61 -2.47 1.27 0.00 3.48 -27 25
Book Value per Share		 ($83.24) $6.35 $4.03 $3.77 $2.42 $2.57 $1.21 $1.21 $0.79 $0.51 $0.82
Tangible Book Value per Share		 ($83.24) $6.35 $4.03 $3.77 $2.42 $2.57 $1.21 $1.21 $0.79 $0.51 $0.82
Total Capital		 95 133 85 110 71 72 56 56 39 33 61
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -94 -135 -90 -115 -78 -81 -64 -64 -43 -65 -68
Capital Expenditures (CapEx)		 1.75 2.20 0.27 0.36 0.03 0.08 0.01 0.25 0.03 -0.01 0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.79 -4.81 -7.79 -6.04 -8.86 -11 -9.39 -9.39 -6.06 -33 -7.92
Debt-free Net Working Capital (DFNWC)		 93 130 82 109 69 33 33 33 21 19 49
Net Working Capital (NWC)		 93 130 82 109 69 33 33 33 21 19 49
Net Nonoperating Expense (NNE)		 22 10 16 12 12 -25 16 19 11 43 -15
Net Nonoperating Obligations (NNO)		 -94 -135 -90 -115 -78 -81 -64 -64 -43 -65 -68
Total Depreciation and Amortization (D&A)		 0.11 1.24 0.65 0.85 0.10 0.63 0.46 0.20 -0.74 -1.06 -1.24
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($83.86) ($2.36) ($2.72) ($1.71) ($1.59) ($0.20) $0.00 $0.00 ($0.56) ($1.02) ($0.19)
Adjusted Weighted Average Basic Shares Outstanding		 373.64K 20.93M 21.07M 29.33M 29.33M 38.31M 0.00 0.00 48.03M 60.99M 78.96M
Adjusted Diluted Earnings per Share		 ($83.86) ($2.36) ($2.72) ($1.71) ($1.59) ($0.20) $0.00 $0.00 ($0.56) ($1.02) ($0.53)
Adjusted Weighted Average Diluted Shares Outstanding		 373.64K 20.93M 21.07M 29.33M 29.33M 38.31M 0.00 0.00 48.03M 60.99M 79.74M
Adjusted Basic & Diluted Earnings per Share		 ($83.86) ($2.36) ($2.72) ($1.71) ($1.59) ($0.20) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 373.64K 15.42M 20.49M 27.51M 29.35M 29.48M 0.00 0.00 49.04M 68.14M 83.99M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.64 -26 -40 -34 -34 -31 -27 -23 -16 -19 -30
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Corvus Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Corvus Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 48,965,862.00 49,038,582.00 49,038,582.00 62,551.00 62,551,281.00 - 68,135,796.00 77,114,636.00 74,514,039.00 74,681,872.00 83,992,407.00
DEI Adjusted Shares Outstanding		 48,965,862.00 49,038,582.00 49,038,582.00 62,551.00 62,551,281.00 - 68,135,796.00 77,114,636.00 74,514,039.00 74,681,872.00 83,992,407.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.12 -0.12 -0.12 -68.14 -0.64 - 0.22 -0.10 -0.14 -0.17 -0.16
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 61.78% -3.19% 5.12% 26.04% -603.10% -85.63% 334.10% -97.89% 72.90% - -199.51%
EBIT Growth		 63.43% 0.26% 4.07% 26.73% -621.24% -84.96% 343.20% -100.24% 73.64% - -197.83%
NOPAT Growth		 55.42% 30.19% 4.88% -5.57% -30.49% -43.43% -126.68% -72.87% -45.72% - -4.96%
Net Income Growth		 59.54% 32.22% 27.59% 34.46% -570.28% -82.07% 366.50% -87.66% 74.74% - -190.12%
EPS Growth		 62.50% 0.00% 29.41% 50.00% -400.00% -76.92% -8.33% -42.86% 80.00% - -15.38%
Operating Cash Flow Growth		 21.58% 31.54% 36.42% -4.94% -16.32% -63.83% -60.23% -5.40% -51.34% - -25.55%
Free Cash Flow Firm Growth		 -81.65% -31.18% -0.38% 135.05% 451.34% 391.61% -45.08% -835.12% -234.82% - -38.69%
Invested Capital Growth		 54.37% 43.11% 17.21% -105.80% -797.37% -596.08% -43.79% 47.72% 87.73% - 5.96%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 1.18% 0.43% -10.97% 32.27% -839.47% 73.71% 239.95% -157.26% -28.64% - -19.38%
EBIT Q/Q Growth		 1.10% -1.64% -10.65% 34.13% -873.56% 73.94% 245.49% -154.24% -28.18% - -21.77%
NOPAT Q/Q Growth		 1.10% -1.64% -10.65% 5.09% -22.24% -11.72% -74.88% 27.62% -3.04% - -21.77%
Net Income Q/Q Growth		 7.73% -10.88% 14.31% 25.24% -843.62% 69.88% 225.43% -152.64% -26.99% - -11.13%
EPS Q/Q Growth		 14.29% -8.33% 7.69% 41.67% -757.14% 61.67% 43.48% 23.08% -20.00% - 16.67%
Operating Cash Flow Q/Q Growth		 -4.04% 4.91% 0.19% -6.28% -15.33% -33.92% 2.39% 30.09% -65.59% - -12.87%
Free Cash Flow Firm Q/Q Growth		 -99.72% 24.09% 27.60% 131.94% 1,901.72% -36.99% -136.02% -61.82% -267.12% - 68.11%
Invested Capital Q/Q Growth		 10.81% 7.33% -5.27% -136.52% -288.91% 28.12% 78.25% 14.00% 8.74% - 0.08%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 116.85% 126.75% 96.02% 115.66% 101.73% 121.87% 96.57% 105.11% 103.28% - 104.58%
Interest Burden Percent		 92.36% 92.89% 94.95% 89.46% 98.59% 95.09% 103.45% 92.25% 93.02% - 88.01%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -55.41% -57.02% -60.46% -44.91% -200.48% -174.85% -100.13% -68.67% -35.82% - -30.46%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -55.41% -57.02% -60.46% -44.91% -200.48% -174.85% -100.13% -68.67% -35.82% - -30.46%
Return on Equity Simple (ROE_SIMPLE)		 -68.17% 0.00% -74.50% 0.00% 0.00% 0.00% -83.93% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.89 -3.96 -4.38 -4.15 -5.08 -5.67 -9.92 -7.18 -7.40 -8.55 -10
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.38% -5.02% -2.85% -0.18% -66.25% -11.95% 53.17% -1.10% -4.11% - -2.16%
Return On Investment Capital (ROIC_SIMPLE)		 - -10.23% -13.12% -8.11% -40.93% -17.42% -20.12% -8.95% -10.31% -13.97% -4.33%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.56 -5.65 -6.25 -4.12 -40 -10 15 -8.25 -11 -12 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.78 -5.75 -6.38 -4.32 -41 -11 15 -8.55 -11 -12 -15
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.61 2.23 2.62 0.00 26.62 10.56 4.39 3.84 7.65 - 5.11
Price to Tangible Book Value (P/TBV)		 1.61 2.23 2.62 0.00 26.62 10.56 4.39 3.84 7.65 - 5.11
Price to Revenue (P/Rev)		 483.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 150.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 12.48 34.63 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.15 -1.13 -1.13 -1.17 -1.87 -1.51 -1.14 -1.13 -1.59 - -1.05
Leverage Ratio		 1.21 1.20 1.20 1.22 1.95 1.61 1.20 1.17 1.65 - 1.08
Compound Leverage Factor		 1.12 1.12 1.13 1.09 1.93 1.53 1.25 1.08 1.54 - 0.95
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 -2.99 -2.60 -4.13 -7.03 -7.21 -2.56 5.44 14.54 31.33 - 57.44
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.53 4.07 3.40 3.62 0.92 1.54 4.90 8.91 8.29 - 19.81
Quick Ratio		 4.41 3.96 3.30 3.55 0.90 1.47 4.77 8.76 8.14 - 19.55
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -9.79 -7.43 -5.38 1.72 34 22 -7.81 -13 -46 -34 -11
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -22,952.78% -5,112.39% 0.00% - -11,400.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 633.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 633.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.95 -4.59 -4.83 -11 -44 -32 -6.95 -5.97 -5.45 -6.54 -6.53
Invested Capital Turnover		 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 5.90 3.48 1.00 -5.87 -39 -27 -2.12 5.45 39 25 0.41
Enterprise Value (EV)		 22 43 49 -63 273 279 160 222 472 - 982
Market Capitalization		 71 86 87 0.11 330 344 217 308 549 - 1,229
Book Value per Share		 $0.90 $0.79 $0.68 $818.95 $0.20 $0.51 $0.72 $1.04 $0.96 $0.82 $2.87
Tangible Book Value per Share		 $0.90 $0.79 $0.68 $818.95 $0.20 $0.51 $0.72 $1.04 $0.96 $0.82 $2.87
Total Capital		 44 39 33 51 12 33 49 80 72 61 241
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -49 -43 -38 -63 -57 -65 -56 -86 -77 -68 -247
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.11 0.00 0.03 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.37 -6.06 -6.00 -12 -45 -33 -8.00 -7.13 -6.82 -7.92 -8.88
Debt-free Net Working Capital (DFNWC)		 26 21 16 35 -3.49 19 36 67 59 49 228
Net Working Capital (NWC)		 26 21 16 35 -3.49 19 36 67 59 49 228
Net Nonoperating Expense (NNE)		 2.11 2.70 1.32 0.11 35 6.44 -25 0.82 2.76 3.77 3.28
Net Nonoperating Obligations (NNO)		 -49 -43 -38 -63 -57 -65 -56 -86 -77 -68 -247
Total Depreciation and Amortization (D&A)		 -0.22 -0.10 -0.13 -0.20 -0.50 -0.22 -0.27 -0.31 -0.43 -0.24 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 -4,306.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 17,429.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 17,429.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.12) ($0.13) ($0.12) ($0.07) ($0.60) ($0.23) $0.21 ($0.10) ($0.12) ($0.18) ($0.15)
Adjusted Weighted Average Basic Shares Outstanding		 48.97M 48.03M 49.04M 59.71M 66.70M 60.99M 72.13M 77.77M 82.84M 78.96M 90.00M
Adjusted Diluted Earnings per Share		 ($0.12) ($0.13) ($0.12) ($0.07) ($0.60) ($0.23) ($0.13) ($0.10) ($0.12) ($0.18) ($0.15)
Adjusted Weighted Average Diluted Shares Outstanding		 48.97M 48.03M 49.04M 59.71M 66.70M 60.99M 75.15M 77.77M 82.84M 79.74M 90.00M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.04M 49.04M 62.55K 62.55M 64.26M 68.14M 77.11M 74.51M 74.68M 83.99M 84.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.89 -3.96 -4.38 -4.15 -5.08 -5.67 -6.95 -7.18 -7.40 -8.55 -10
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Key takeaways from Corvus Pharmaceuticals (CRVS) quarterly financials over the last four years (through Q4 2025) show a biotech company that is not yet generating revenue, relies on external funding, and experiences volatility in profitability. The bullets below are ordered with the positives first, then neutrals, then negatives.

  • Q4 2024 financing activities produced a net cash inflow of about $18.6 million, providing a meaningful liquidity runway.
  • In Q1 2025, the company posted a quarterly net income of about $15.19 million (a rare profit in the period).
  • Q4 2025 shows a positive net change in cash and equivalents of about $1.71 million for the quarter, signaling a modest quarterly liquidity uptick.
  • Q4 2025 investing activities contributed a net cash inflow of about $10.88 million, aided by $24.32 million in sale/maturity of investments versus $13.42 million in purchases.
  • Revenue is effectively zero across most quarters, indicating the company remains in pre-revenue biotech development mode.
  • R&D and SG&A expenses remain material and trending higher over 2024–2025, contributing to ongoing operating losses.
  • Share count and per-share metrics fluctuate, with restatements and mix of basic/diluted EPS, reflecting ongoing capital structure changes.
  • The company continues to post net losses across most quarters, including -$12.32 million in Q4 2025 and -$10.16 million in Q3 2025.
  • Operating cash flow is negative in most periods (e.g., -$9.19 million in Q4 2025 and -$9.57 million in Q3 2025), indicating cash burn from core operations.
  • Retained earnings are deeply negative, with a cumulative deficit around -$400 million by Q4 2025, underscoring a long-running accumulated loss position.
05/09/26 09:57 AM ETAI Generated. May Contain Errors.

Corvus Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Corvus Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Corvus Pharmaceuticals' net income were at -$15.28 million at the end of 2025, a 75.5% decrease from 2024, and a 51.2% decrease since 2015. View Corvus Pharmaceuticals' forecast to see where analysts expect Corvus Pharmaceuticals to go next.

Corvus Pharmaceuticals' total operating income in 2025 was -$42.97 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $42.97 million

Over the last 10 years, Corvus Pharmaceuticals' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Corvus Pharmaceuticals' total liabilities were at $9.91 million at the end of 2025, a 72.7% decrease from 2024, and a 162.3% increase since 2015.

In the past 10 years, Corvus Pharmaceuticals' cash and equivalents has ranged from $4.11 million in 2015 to $63.46 million in 2021, and is currently $4.58 million as of their latest financial filing in 2025.

Over the last 10 years, Corvus Pharmaceuticals' book value per share changed from -83.24 in 2015 to 0.82 in 2025, a change of -101.0%.


Related Companies

Financial statements for NASDAQ:CRVS last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel